Chronic Myeloid Leukemia Presenting with Priapism

Farhan S1, Anjum F1, Al-Qahtani FS2 and Al-Anazi KA3*

1Senior Medical Residents, Section of Hematology, Department of Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
2Assistant Professor and Consultant Hematopathologist, Division of Hematopathology, Department of Pathology, King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia
3Consultant Hemato-Oncologist, Section of Adult Hematology and Oncology, Department of Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Abstract

Chronic myeloid leukemia is a chronic myeloproliferative neoplasm that usually presents with an elevated white blood cell count and an enlarged spleen. Presentation with priapism is rather exceptional and is usually caused by leukostasis due to hyperleukocytosis. Priapism in chronic myeloid leukemia is a medical emergency that requires local therapies, symptomatic treatment as well as specific measures aimed at rapid control of the leukemia in the form of cytoreductive therapy, early initiation of targeted therapy with tyrosine kinase inhibitors in addition to leukapheresis in order to decrease the elevated leukocytic count as quickly as possible. A young patient with chronic myeloid leukemia who presented with priapism to King Khalid University Hospital in Riyadh is presented. The diagnostic work up and the lines of management are discussed.

Keywords: Chronic myeloid leukemia; Priapism; Hyperleukocytosis; Leukapheresis; Tyrosine kinase inhibitors.

Introduction

Priapism is a medical and surgical emergency that is characterized by prolonged and painful erection of the penis unassociated with any sexual arousal or desire. Approximately 50% of patients having priapism are at risk of impotence, despite appropriate therapy. If untreated, priapism may lead to penile necrosis and permanent erectile dysfunction [1-7]. Priapism can occur at any age. It has bimodal peak incidence with the first peak mainly occurring in children with Sickle Cell Disease (SCD) between 5 and 10 years of age and the second peak developing in sexually active adult males belonging to the age group 20 to 50 years. The incidence of priapism is 1.5 per 100,000 people. Priapism can either be idiopathic or secondary to several medical conditions (Table 1) [1-5,7]. Idiopathic priapism accounts for 64% of all cases of priapism. About 20% of cases of priapism are caused by hematological disorders [2,4,5]. In children, SCD accounts for 67% of cases while leukemia accounts for 15% of cases of priapism. The hematological disorders [2,4,5]. In children, SCD accounts for 67% of cases while leukemia accounts for 15% of cases of priapism. The incidence of priapism in adult leukemia ranges between 1 and 5% [3-6]. In patients with leukemia, 50% of cases of priapism are due to Chronic Myeloid Leukemia (CML) and priapism is less common in patients with acute leukemia than in patients with chronic leukemia. Priapism can be classified into low flow type and high flow priapism (Table 2) [1,2,4,6].

Case Presentation

On 11/06/2013, a previously healthy 38 years Saudi male was referred from a local hospital to King Khalid University Hospital (KKUH) for treatment of painful erection of his penis that had lasted for 30 hours. There was no history of trauma, intake of new medications, exposure to radiation, fever or chills but the patient gave history of weight loss of 20 kg over 6 months in addition to dragging sensation in the abdomen and malaise. There was no history of bleeding from any site, dyspnea, headache, blurring of vision, convulsions or loss of consciousness. On arrival to the emergency room, his vital signs revealed pulse: 109/min, blood pressure: 136/72 mmHg, respiratory rate: 20/minute and temperature: 36.7°C. The physical examination revealed conjunctival pallor, but no: external palpable lymphadenopathy, jaundice, ecchymoses, skin rashes or leg edema. Abdominal examination showed no tenderness, impalpable liver and splenomegaly of 18 cm below the left costal margin. Examination of cardiovascular, respiratory and central nervous systems did not reveal any abnormality. The penis was erect, firm and tender with superficial venous engorgement. The testicles were bilaterally descended. Digital rectal examination revealed no enlargement or tenderness of the prostate. Complete Blood Count (CBC) showed white blood cell (WBC) count: 378×10⁹/l, hemoglobin: 105 g/l, platelets: 155×10¹⁰/l. Differential cell count revealed: 57% neutrophils, 15% metamyelocytes, 20% myelocytes, 2% promyelocytes and there were no blast cells on peripheral blood smear. Renal, hepatic and coagulation profiles were all normal. Uric acid was 429 μmol/l, lactate dehydrogenase was 688 u/l.

As the patient presented with priapism and before obtaining the results of CBC, he was initially seen by urologists. Because of the prolonged duration of priapism, treatment was initiated by performing cavernosal aspiration and irrigation. Unfortunately, there was incomplete relief of the erection by the procedure. Then the patient was admitted to KKUH initially under care of urologists. Later on-call hematologists were consulted to see the patient. After reviewing his clinical findings, laboratory investigations and making sure that CML was the most likely cause of his priapism, he was commenced on intravenous fluids, allopurinol and cytoreductive therapy with hydroxyurea 4 g/day. Also, leukapheresis was initiated and the patient received a total of three sessions of leukapheresis. Bone marrow biopsy was performed and it confirmed the diagnosis of CML (Figures 1-4).

*Corresponding author: Dr. Khalid Ahmed Al-Anazi, Consultant Hemato-Oncologist, Section of Adult Hematology and Oncology, Department of Medicine, College of Medicine, King Khalid University Hospital, King Saud University, P.O. Box: 2925, Riyadh 11461, Saudi Arabia. Tel: 966-011-4671546; Fax: 966-011-4671546; E-mail: kaq_alanazi@yahoo.com

Received: November 27, 2014; Accepted: December 16, 2014; Published: December 23, 2014

Citation: Farhan S, Anjum F, Al-Qahtani FS, Al-Anazi KA (2014) Chronic Myeloid Leukemia Presenting with Priapism. J Leuk 3: 171. doi:10.4172/2329-6917.1000171

Copyright: © 2015 Farhan S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The patient achieved major molecular response (MMR) of his CML. He was asymptomatic, his clinical examination showed an impalpable spleen, and his CBC was normal and his BCR-ABL taken 2 weeks earlier was negative. He was continued on imatinib, given new follow-up appointments, and was planned for a new molecular evaluation of his disease in 3 months.

**Discussion**

CML is a chronic myeloproliferative neoplasm, characterized by Philadelphia chromosome and results from clonal expansion of pluripotent hematopoietic stem cells containing the active BCR-

---

### Table 1: Shows causes of priapism.

| Type of priapism | Low flow (ischemic, venous) priapism | High flow (non-ischemic, arterial) priapism |
|------------------|--------------------------------------|-------------------------------------------|
| **Etiology and associations** | - Idiopathic  
- Drug induced  
- Neurologically mediated  
- Tumor infiltration  
- Hyperviscosity states: thrombophilia, hemoglobinopathies and hyperleukocytosis | - Trauma to perineum or genitalia |
| **Clinical manifestations** | - Painful and rigid erection.  
- Irreversible erectile dysfunction if condition persists longer than 24-48 hours. | - Painless erection at clinical presentation  
- Irreversible cellular damage and fibrosis are rare |
| **Pathogenesis and course** | - Intracavernosal blood sampling: acidosis and low oxygen tension.  
- Blockade of venous drainage from emissary venules causes intra-cavernosal blood stasis leading to accumulation of deoxygenated blood within the cavernous tissue thus causing trabecular interstitial edema and ultrastructural changes in trabecular smooth muscle. Functional transformation of these cells to fibroblast like cells ultimately causes cellular damage and fibrosis. | - Intracavernosal blood sampling: bright red oxygenated blood.  
- * Increased blood flow in arteries causes an increase in blood flow into cavernosal sinusoids thus overwhelming the venous outflow. |
| **Management** | - Local penile or systemic anesthesia: spinal anesthesia, circumferential penile block.  
- Intracavernosal instillation of a sympathomimetic agent e.g. phenylephedrine to induce detumescence.  
- Surgical shunt designed to divert blood away from corpus cavernosum is indicated in case of failure of the above measures.  
- Immediate aspiration and irrigation of the corpora cavernosa.  
- Anticoagulants and antiplatelet agents may be indicated.  
- More common; actual medical and surgical emergency. | - Perineal trauma causes injury to internal pudendal artery and this establishes a fistula between cavernosal artery and corpus cavernosum thus ultimately leading to unregulated blood flow.  
- Treatment can be given on an elective basis.  
- Less common; not a medical emergency. |

---

Cytogenetic analysis revealed the presence of Philadelphia chromosome and molecular studies confirmed the presence of BCR-ABL transcript, so the patient was commenced on imatinib 400 mg/day. Five days after admission, priapism resolved and his leukocyte count dropped to 53×10^9/l. Later on, the patient became asymptomatic, he remained stable clinically and his WBC count continued to drop which allowed discontinuation of hydroxyurea and allopurinol.

On 11/11/2013, the patient was discharged on imatinib 400 mg/day and he was given regular follow-up appointments at the hematology outpatient clinic. Six months after starting imatinib therapy, the patient achieved major molecular response (MMR) of his CML. The patient was last seen on 11/23/2014. He was asymptomatic, his clinical examination showed an impalpable spleen and his CBC was normal and his BCR-ABL taken 2 weeks earlier was negative. He was continued on imatinib, given new follow-up appointment and was planned for a new molecular evaluation of his disease in 3 months.
ABL fusion gene which is produced by a reciprocal chromosomal translocation between the ABL oncogene on chromosome 9 and the BCR gene on chromosome 22 [8-12]. The disease is often discovered accidentally when the patient presents with an elevated WBC count and/or an enlarged spleen. The most common clinical manifestations of CML are: anorexia, malaise, weight loss, sweating, bleeding episodes due to platelet dysfunction, abdominal fullness and pain or dragging sensation in the abdomen due to progressive enlargement of the spleen. Involvement of extramedullary tissues or sites such as liver, lymph nodes and skin is generally limited to patients having progressive disease [10]. At times, patients may present with leukostatic complications of hyperleukocytosis such as thromboembolic phenomena, hearing loss or priapism [4,13-15].

Introduction of imatinib and other Tyrosine Kinase Inhibitors (TKIs) has radically improved the outcome of patients with CML and some other diseases with BCR-ABL expression [8]. Imatinib was the first TKI to be licensed for use in treating patients with CML in Chronic-Phase (CP) and its introduction was associated with substantial improvements in response and survival compared with previous therapies [11]. Imatinib was approved by the food and drug authority in the United States of America as first-line treatment for newly diagnosed CML in December 2002, following an International Randomized Study (IRIS) initiated in June 2000 comparing imatinib as a single daily dose of 400 mg to interferon plus cytarabine in newly diagnosed patients with CML in CP [16]. The IRIS study showed the outstanding effectiveness of imatinib and its superiority with respect to the rates of Complete Hematological Response (CHR), Major Cytogenetic Response (MCR) and Complete Cytogenetic Response (CCrR). However, imatinib at dose of 400mg per day is still the gold standard first-line treatment for CML [17]. If the patient has a suboptimal response whilst on imatinib therapy, shifting to a second generation TKI such as dasatinib or nilotinib is justified in order to have a more optimal response as these agents have shown higher efficacy in clinical trials in imatinib-resistant or intolerant CML patients compared to imatinib treatment [10,18]. Other therapeutic options in case of suboptimal response to imatinib include: (1) escalation of the dose of imatinib, (2) allogeneic hematopoietic stem cell transplantation (HSCT), and (3) the use of agents that are being evaluated in clinical trials.

Approximately 20-30% of patients with CML fail imatinib therapy and develop resistance to the drug. These patients require alternative therapies. Therefore, it is vital to identify high risk patients at presentation of CML and start them on appropriate alternative therapies as early as possible [10,19]. Patients with CML harboring specific mutations such as T315 I remain resistant not only to first line but also to second line TKIs and require additional third generation inhibitors such as ponatinib to overcome resistance induced by these point mutations [8,18]. In patients with CML having accelerated phase or blast cell crisis, therapeutic options are limited and survival...
is significantly shorter than that of patients with CP-CML even in the presence of powerful targeted therapies [20]. Allogeneic HSCT is still the only potentially curative therapy for CML and is the most valid therapeutic option that can be offered before the disease reaches the blastic phase [17].

In a comparative study, the rates of CyR, MMR and Complete Molecular Response (CMR) in adolescents and young adults with CML treated upfront with TKIs were found to be lower than those in older patients but the overall survival was similar between the two groups. So, additional research in adolescents and young adults is needed to optimize CML treatment in this age group [21]. The aim of TKI therapy in patients with CML is to obtain ideal hematological, cytogenetic and molecular responses at certain and critical time points. Molecular monitoring of BCR-ABL transcripts by performing real time, quantitative, polymerase chain reaction has proven to be the most sensitive available method and has shown prognostic impact with regard to progression-free survival. The depth of response obtained with TKI therapy and the time to achieve this response are important in predicting the prognosis in patients with CML [17,20,22]. Careful and regular monitoring of CML patients on TKI treatment according to the European Leukemia Net CML guidelines and recommendations is of vital importance as timely and accurate monitoring is the key to optimizing patient management [18,20]. Excessive monitoring may have an economic cost, whilst failure to optimize TKI therapy may result in CML disease progression and death. Additionally, achievement of optimal responses and minimizing healthcare costs require full adherence of patients with CML to TKI therapy [23]. The patient presented achieved MMR 6 months after diagnosis and he achieved CMR 12 months after starting imatinib therapy.

Hyperleukocytosis is usually defined as having circulating blast cell count or WBC count exceeding 50 to 100 x 10⁹/l. Hyperleukocytosis is usually encountered at the presentation of acute myeloid leukemia, acute lymphoblastic leukemia, CML or chronic lymphocytic leukemia [14,24,25]. Hyperleukocytosis leads to leukostasis that may be complicated by: hearing loss, papilledema, cerebellar dysfunction, impairment of memory function, intracranial hemorrhage, respiratory depression or failure, acute renal failure and priapism [14,15,24,26-28]. Treatment of hyperleukocytosis and leukostasis includes: cytoreductive therapy with hydroxyurea, cyclophosphamide or cytosine arabinoside, and therapeutic leukapheresis.

Although priapism is a rare and a rather exceptional presentation in male patients with CML, physicians should be aware of this disorder in order to ensure timely management [1,2,6,13]. At times, CML presents with an unexpected emergency such as priapism and the diagnosis of CML can only be made retrospectively after obtaining results of laboratory investigations. Hyperleukocytosis in CML causes formation of leukocyte aggregates or leukostasis which leads to the formation of thrombi in small blood vessels that ultimately causes vascular obstruction [4,13]. In our patient, hyperleukocytosis caused leukostasis and possibly microthrombi in the cavernosal circulation which precipitated priapism. The following five pathophysiological mechanisms of priapism in CML have been postulated: (1) venous congestion of the corpora cavernosa resulting from mechanical pressure exerted by the enlarged spleen on the abdominal veins, (2) sludging of leukemia cells in the corpora cavernosa and the dorsal veins of the penis, (3) local infiltration of sacral nerves by leukemia cells, (4) central nervous system infiltration by leukemia, and (5) hyperleukocytosis causing elevation of whole-blood viscosity and this ultimately causing complication due to vascular obstruction [2,4].

In a patient presenting with priapism, the following are essential to make diagnosis of the cause of presentation: detailed history, through physical examination, appropriate laboratory investigations including CBC, differential cell count and peripheral blood film, cavernosal blood gas analysis and color duplex ultrasonography [6]. However, early intervention allows the best chance for full recovery. Currently, there are no standard protocols for management of priapism in CML patients and optimal management is still controversial. Old therapies reported in literature included: local radiotherapy, with or without open surgical shunting. New therapies include: (1) cytoreductive therapies with chemotherapeutic agents such as hydroxyurea, (2) leukapheresis in case of hyperleukocytosis, (3) allopurinol, hydration and symptomatic treatment, and (4) early initiation of TKI therapy with agents such as imatinib [3,7]. The patient presented was initially tried on local measures then he received: cytoreductive therapy in the form of high dose hydroxyurea, leukapheresis and TKI therapy in the form of imatinib, which allowed rapid reduction of the disease burden and rapid reversal of his priapism.

**Conclusion**

Priapism is a rare presentation of CML. Once it is encountered, the diagnostic procedures should be performed urgently and the patient should be commenced on: cytoreductive therapy, TKI therapy and leukapheresis in case of hyperleukocytosis as soon as possible not only to control priapism, but also to prevent further complications.

**Acknowledgements**

We are grateful to all medical, nursing and technical staff at KKUH who participated in the management of the patient presented.

**References**

1. Jana K, Aggarwal R, Gawande A, Lal M (2013) Priapism: a chronic myeloid leukemia harbinger in exigency. Ann Trop Med Public Health 6 (5): 583-585.
2. Chang MW, Tang CC, Chang SS (2003) Priapism—a rare presentation in chronic myeloid leukemia: case report and review of the literature. Chang Gung Med J 26: 288-292.
3. Tazi I (2009) Priapism as the first manifestation of chronic myeloid leukemia. Ann Saud Med 29: 412.
4. Jameel T, Mehmood K (2009) Priapism - an unusual presentation in chronic myeloid leukemia: case report and review of the literature. Biomedica 25: 197-199.
5. Yu KP, Hwang WS, Lee WC, Lin JS, Twu BH (1985) Priapism in patients with chronic myeloid leukemia: report of two cases. J Med Sci 6 (1): 87-92.
6. Hazra SP, Priyadarshy V, Gogoi D, Sharma PK, Pal DK, et al. (2013) Pediatric priapism: a rare first manifestation of leukemia. APSF J Case Rep 4: 39.
7. Tsai CH, Tsan YT, Hu SY, Lin TC, Hu WH, et al. (2008) Priapism as an initial manifestation of chronic myeloid leukemia: a case report. J Taiwan Emerg Med 10 (3): 100-104.
8. Trela E, Glowacki S (2014) Therapy of chronic myeloid leukemia: twilight of the imatinib era? ISRN Oncol 2014: 596483.
9. Fausel C (2007) Targeted chronic myeloid leukemia therapy: seeking a cure. J Manag Care Pharm 13: 8-12.
10. Banar Y, Saydam G (2012) Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. J Blood Med 3: 139-150.
11. Ferdinand R, Mitchell SA, Batson S, Tumur I (2012) Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 3: 51-76.
12. Hu B, Savani BN (2014) Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Eur J Haematol 93: 179-186.
13. Ocheri S, Ibegbulam OG, Olusina DB, Oyekunle AA, Durosimiri MA (2010)
Chronic myeloid leukemia presenting as priapism: a report of 2 cases and review of literature. J Coll Med 15 (2).

14. Rowe JM, Lichtman MA (1984) Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood 63: 1230-1234.

15. Tsai CC, Huang CB, Sheen JM, Wei HH, Hsiao CC (2004) Sudden hearing loss as the initial manifestation of chronic myeloid leukemia in a child. Chang Gung Med J 27: 629-633.

16. Sacha T (2014) Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis 6: e2014007.

17. Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, et al. (2012) Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii72-77.

18. Menon H (2013) Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome. South Asian J Cancer 2: 38-43.

19. Deininger MW (2008) Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program.

20. Haznedaroglu IC (2014) Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). Mediterr J Hematol Infect Dis 6: e2014009.

21. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, et al. (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97 (7): 1029-1035.

22. Agarwal MB (2014) Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting. Indian J Med Paediatr Oncol 35: 10-16.

23. de Almeida MH, Fogliatto L, Couto D (2014) Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Rev Bras Hematol Hemoter 36: 54-59.

24. Blum W, Porcu P (2007) Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 33: 350-354.

25. Galbraith PR, Valberg LS, Gruner PH, Brown GM (1965) The mechanism of the leukocytosis in chronic myeloid leukemia. Ann Inter Med 62 (5): 1085.

26. Resende LS, Coradazzi AL, Rocha-Júnior C, Zanini JM, Niero-Melo L (2000) Sudden bilateral deafness from hyperleukocytosis in chronic myeloid leukemia. Acta Haematol 104: 46-49.

27. Kapur S, Wax M, Miles L, Hussain A (2013) Permanent sensorineural deafness in a patient with chronic myelogenous leukemia secondary to intracranial hemorrhage. Case Rep Hematol 2013: 894141.

28. Naithani R, Chandra J, Mathur NN, Narayan S, Singh V (2005) Hearing loss in chronic myeloid leukemia. Pediatr Blood Cancer 45: 54-56.